Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370587 · ClinicalTrials.gov registry record · Phase 1
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 study of Melanoma and Solid Tumor, sponsored by ImmVira Pharma Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT04370587: Recruiting Phase 1 study of Melanoma and Solid Tumor, sponsored by ImmVira Pharma Co..
NCT04370587 is a Phase 1 study of Melanoma and Solid Tumor that is actively recruiting participants, run by ImmVira Pharma Co.. The registered enrollment target is 30 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04370587, a Phase 1 study of Melanoma and Solid Tumor, is actively recruiting participants, sponsored by ImmVira Pharma Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
Primary Outcome
Number of participants in dose escalating cohorts with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.
Conditions Studied
Interventions
- BIOLOGICAL T3011
- COMBINATION_PRODUCT T3011 + pembrolizumab
Study Locations (9)
Other
- Southern Oncology - Bedford Park
- Peninsula & South Eastern Haematology and Oncology Group - Frankston
- The Alfred - Melbourne
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- Mary Crowley Cancer Research - Dallas
Virginia
- Virginia Cancer Specialists - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2027-01-10 |
| Phase | Phase 1 |
What NCT04370587 shows while recruiting
NCT04370587 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower).
The record links to 6 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which T3011 is the first listed.
NCT04370587 lists 9 locations in 6 states (Other, Massachusetts, Arizona).
Frequently Asked Questions
What is clinical trial NCT04370587 about?
NCT04370587 is a clinical study titled "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors". This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.
What is the current status of trial NCT04370587?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-09-17. Estimated completion is 2027-01-10.
What conditions does trial NCT04370587 study?
This clinical trial studies the following conditions: Melanoma, Solid Tumor, Sarcoma, NSCLC, Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04370587?
The interventions under investigation include: T3011 (BIOLOGICAL), T3011 + pembrolizumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04370587?
This trial is sponsored by ImmVira Pharma Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04370587 being conducted?
This trial has 9 study locations across Arizona, Massachusetts, Pennsylvania, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04370587's enrollment target sits among peer trials
30 197th of 266 higher than 63 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI